Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China
Cadonilimab combined with chemotherapy may be cost-effective in Chinese patients with elevated PD-L1 expression. However, its broader use in other patient subgroups or countries requires significant price reductions. These findings provide important guidance for future reimbursements and pricing decisions.
Authors
- Huiqing Jiang (ORCID: https://orcid.org/0000-0001-8706-0943)
- Mei Li (ORCID: https://orcid.org/0000-0001-5646-9172)
- Qiang Xiao (ORCID: https://orcid.org/0000-0001-8919-403X)
- Zhiyuan Zhou (ORCID: https://orcid.org/0000-0002-2896-5862)
- W.J. Lang (ORCID: https://orcid.org/0009-0007-3583-9518)
- Xianling Zhao
Institutions
- Nanxi Mountain Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1618726
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00